Genmab A/S February 2025 SEC Report: Key Insights & Annual Meeting Announcement

Here are the key insights extracted from the provided section of the financial report:

1. Filing Type: The document is a Form 6-K, which is used by foreign private issuers to report significant events to the U.S. Securities and Exchange Commission (SEC).
2. Company Information:

• Name: Genmab A/S
• Commission File Number: 001-38976
• Address: Carl Jacobsens Vej 30, 2500 Valby, Denmark
• Contact: +45 70 20 27 28

3. Reporting Period: The report is for the month of February 2025.
4. Incorporation by Reference: This report will be incorporated by reference in Genmab A/S’s registration statements filed on Form S-8. The associated file numbers are:

• 333-232693
• 333-253519
• 333-262970
• 333-277273
• 333-284876

5. Signature:

• Signed by Anthony Pagano, who holds the title of Executive Vice President & Chief Financial Officer.
• Date of Signature: February 13, 2025.

6. Exhibit Index:

• An exhibit is referenced as 99.1, which includes a company announcement dated February 13, 2025, about the notice to convene the Annual General Meeting of Genmab A/S.

This information is significant as it outlines the company's compliance with SEC reporting requirements, provides key contact and business information, and highlights upcoming corporate governance actions (the Annual General Meeting).